Key result
Treatment with the selective TRPV4 antagonist HC-067047 significantly reduced myocardial infarct size compared to vehicle (15% vs 36%) in a murine model of myocardial ischemia/reperfusion injury.
Why the study?
Does modulation of TRPV4 affect hypoxia/reoxygenation injury in cardiomyocytes and myocardial ischemia/reperfusion injury in mice?
Population
H9C2 cells, neonatal rat ventricle myocytes, and adult male C57BL/6 mice subjected to hypoxia/reoxygenation…
Comparison
TRPV4 antagonist HC-067047 or TRPV4 agonist… vs Vehicle/saline control.
Design
Preclinical, Blinded observer for infarct size calculation and…
Follow-up
24 hours post-reperfusion
Authors
Loading...
Should not yet change practice; extends TRPV4 as a target in animal I/R models but leaves open human translation.
Does modulation of TRPV4 affect hypoxia/reoxygenation injury in cardiomyocytes and myocardial ischemia/reperfusion injury in mice?
Absolute Event Rate: 15% vs 36%
p-value: p=<0.001
Inhibition of TRPV4 attenuates myocardial ischemia/reperfusion injury by reducing calcium influx, ROS generation, and mitochondrial dysfunction.
Wu et al. (2017) studied Myocardial ischemia/reperfusion injury. HC-067047 (TRPV4 antagonist) vs. Vehicle was evaluated on Myocardial infarct size (% of area at risk) (p=<0.001). Treatment with the selective TRPV4 antagonist HC-067047 significantly reduced myocardial infarct size compared to vehicle (15% vs 36%) in a murine model of myocardial ischemia/reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: